Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
Stablecoin Development Corporation, formerly NovaBay Pharmaceuticals, reports developments tied to its transition from a pharmaceutical and eyecare-products issuer to an on-chain holding company focused on the Sky protocol ecosystem. Company updates include SKY token holdings, staking activity, strategic investment activity, and the completed corporate name and ticker change from NovaBay Pharmaceuticals and NBY to Stablecoin Development Corporation and SDEV.
Earlier NovaBay news centered on Avenova eyecare products, the completed sale of the Avenova business and related assets, NYSE American listing compliance, shareholder meetings, proxy matters, capital-structure actions, and proposals related to the company’s corporate direction.
NovaBay Pharmaceuticals announces special promotions on Avenova eyecare products for National Dry Eye Awareness Month in July. The company aims to educate the public about dry eye disease, which affects 25 million people in the U.S. Customers can avail a 15% discount and free shipping on Avenova products through Amazon.com and Avenova.com. Special offers are also available for eyecare professionals, particularly those using intense pulsed light (IPL) and thermal pulsation treatments. Avenova's range includes sprays, eye drops, warm compresses, dietary supplements, and health monitors, all designed to provide relief from dry eye symptoms.
NovaBay Pharmaceuticals (NBY) announced that the NYSE American has accepted its compliance plan, allowing the company to remain listed while working towards meeting NYSE listing standards. Following the divestiture of an unprofitable segment, NovaBay is now focusing on its core eyecare business, particularly its Avenova®-branded products. The NYSE American has reviewed the plan and acknowledged NovaBay's potential to regain compliance by October 18, 2025, with quarterly reviews until then. Failure to meet these standards could result in delisting proceedings. The company had previously been notified on April 18 and May 28, 2024, about non-compliance due to inadequate stockholders' equity, but this does not affect its business operations or SEC reporting requirements.
NovaBay Pharmaceuticals announced the approval of all proposals at its 2024 Annual Meeting, including a 1-for-35 reverse stock split. This decision aims to align with the NYSE American's listing standards and enhance stock marketability and liquidity. The reverse stock split will be effective on May 30, 2024, and shares will trade on a split-adjusted basis from May 31, 2024.
Additionally, NovaBay received a notice from NYSE American regarding non-compliance with stockholders’ equity requirements. They have until October 18, 2025, to meet these standards or face potential delisting. The company's recent financial statements included a going concern notice, highlighting ongoing financial challenges.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) introduces an expanded line of Avenova product bundles to address individualized relief from dry eye symptoms. The U.S. market for dry eye treatment is projected to reach $4.86 billion by 2030, with approximately 16 million Americans suffering from dry eye disease. The new Avenova bundles align with optometrists' recommendations for personalized treatment beyond artificial tears, offering easy, affordable, and effective solutions for managing dry eye symptoms.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reported a 13% increase in net product sales driven by higher Avenova®-branded product sales through online channels and branded wound care products. Sales and marketing expenses decreased by 15%, with record sales for Avenova products on Amazon.com. The company remains focused on the eyecare market with efficient digital marketing programs aimed at expanding its customer base.
Financially, product sales for Q1 2024 were $2.6 million, a 13% increase from the prior year, driven by online sales. Gross margin remained stable at 68%. Sales and marketing expenses decreased by 15%, while G&A expenses and R&D expenses saw increases. The company reported a net loss attributable to common stockholders of $3.6 million for Q1 2024.
NovaBay Pharmaceuticals, Inc. (NBY) reports record sales of Avenova-branded products on Amazon.com in April 2024, with a 20% increase from the previous year. The company attributes the success to enhanced marketing programs and the high quality of its products. The U.S. dry eye disease market is projected to reach nearly $5 billion by 2030, indicating potential for further growth.
NovaBay Pharmaceuticals, Inc. (NBY) will release financial results for the first quarter ending March 31, 2024, on May 9, 2024, after the market closes. The company will host an investment community conference call at 4:30 p.m. Eastern time on the same day. Participants can pre-register to receive conference call details or join live by dialing in. A replay will be available after the call.
Summary not available.
Summary not available.
Summary not available.